American Century Companies’s Black Diamond Therapeutics BDTX Stock Holding History
Bought
Maintained
Sold
Other funds holding BDTX
NMC
VCM
American Century Companies's BDTX Position: Q1 2026 in Review
American Century Companies reduced its Black Diamond Therapeutics (BDTX) stake by 16% in Q1 2026, selling an estimated $40.6K and leaving 91,046 shares worth $194K. The position accounts for ﹤0.01% of the portfolio, ranked #2716.
American Century Companies first reported a position in BDTX in Q2 2025 and has held it in 4 quarters since. The position peaked at $350K in Q3 2025. 104 funds tracked by Wall St. Rank hold BDTX as of Q1 2026.
- American Century Companies held 91,046 shares of Black Diamond Therapeutics worth $194K as of Q1 2026.
- American Century Companies sold 17,062 Black Diamond Therapeutics shares in Q1 2026, an estimated $40.6K.
- Black Diamond Therapeutics made up ﹤0.01% of American Century Companies's portfolio in Q1 2026, its #2716 holding.
- American Century Companies first reported a position in Black Diamond Therapeutics in Q2 2025 and has held it in 4 quarters since.
- American Century Companies's Black Diamond Therapeutics position peaked at $350K in Q3 2025.
- 104 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2026.
Based on American Century Companies's 13F filing for Q1 2026, filed 15 May 2026.